Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach ...
Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association ...
While plenty of people are going green in honor of Saint Patrick's Day, one student at East Stroudsburg University is turning ...
Patients with Fuchs endothelial corneal dystrophy with particular genetic markers are at higher risk for surgery and vision loss.
After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...
Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...
MOVE Peds will enroll pediatric FSHD patients across eight clinical sites, capturing both early-onset and later-onset pediatric forms of the disease. Using MRI and functional testing optimized for ...
The Falkirk Herald on MSN21h
Fearless granny, family and friends brave the heights at the Falkirk Wheel for young FrazerA grandmother joined her son and some family friends to abseil 100 feet down from the Falkirk Wheel to raise vital cash for ...
Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease----Data Presented at the 2025 Muscular ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
This weekend kicked off the MDA annual Clinical & Scientific Conference, bringing together the neuromuscular disease ...
Clinical Trials Arena on MSN23h
Dyne’s DMD trial advances patient mobility and dystrophin expressionThe Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback